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Angiotensin II blockade in normal man: Interac:tion of renin and
sodium in maintaining blood pressure. Nine norinotensive volun-
teers underwent six days of sodium-depletion followed by six days
of sodium-repletion. On days six and twelve, the angiotensin II
inhibitor, sar'-ala8-angioeensin II (saralasin), was infused i.v. and
the blood pressure monitored with the subjects first in supine and
then in upright position. The degree of induced sodium-depletion
was varied over a considerable range in order to determine the level
of sodium balance which is critical for maintaining blood pressure
in the absence of the pressor action of angiotensin II. Five subjects
had a cumulative sodium loss of more than 200 mEq, mainly
because of more vigorous diuretic treatment; upon infusion of
saralasin, four exhibited marked hypotension in the erect position.
The fifth became deeply hypotensive while still supine and was
unable to stand up. Hypotension occurred in spite of clinical
evidence of catecholanune oversecretion. In the four patients who
had urinary sodium losses of less than 200 mEq, infusion of the
inhibitor did not reduce their blood pressure. Following sodium-
repletion, none of the nine subjects exhibited a blood pressure
response to the inhibitor. These results suggest that angiotensin II
plays an active role in sustaining normal blood pressure only under
conditions of considerable sodium-depletion.
Blocage de l'angiotensine Ii chez l'homme normal, interaction de
Ia rénine et du sodium dans le maintien de Ia pression artérielle. Neuf
volontaires normotendus ont subi une déplétion suivie d'une réplé-
tion sodée durant 2 périodes de six jours. Les sixiémes et douziémes
jours l'inhibiteur de l'angiotensine 11 sar'-ala-8angiotensine IT
(saralasin), a été administré par voie intraveineuse, tandis que
Ia pression artérielle était enregistrée, d'abord en position couchée
puis en position debout. L'importance de Ia déplétion sodée a
été variée en vue de définir Ic niveau critique nécessaire au
maintien de Ia pression artérielle en l'absence d'activité pressive de
l'angiotensine II. Cinq sujets ont eu une perte cumulée de sodium
de plus de 200 mEq, principalement en raison d'un traitement
diurétique plus important. Lors de Ia perfusion de saralasin
quarte d'entre eux ont développé une hypotension importante en
orthostatisme, Ic cinquiéme a présenté un chute tensionnelle
grave en position couchéc déjà, rendant impossible toute station
debout. L'hypotension est survenue malgré des signes cliniques
de secretion accrue de catécholamines. Chez les quatre sujets
dont Ia perte de sodium a été inférieure a 200 mEq l'inhibiteur
n'a pas entrainé de modification tensionnelle. Après réplétion
sodée, aucun des neuf sujets n'a présenté de modification de
pression en réponse a l'inhibiteur. Ces résultats suggèrent que
l'angiotensine 11 ne joue un role actif dans Ic maintien d'une
pression artérielle normale que dans des conditions de déplétion
sodiquc importante.
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Clinicians and pharmacologists alike have known
for a long time that the mechanisms sustaining nor-
mal blood pressure are extremely efficient. Marked
hypotension is rarely observed in patients and, if
present, is usually associate with severe hypovolemia
due to hemorrhage or excessive loss of sodium
and water, with a failing myocardium, or with dis-
orders of the autonomic nervous system. Moreover,
reduction of blood pressure to hypotensive levels by
pharmacologic means is extremely difficult with most
of the currently available antihypertensive drugs.
Notwithstanding, relatively few details are known
about the mechanisms which are responsible for nor-
mal blood pressure regulation.
During the last decade, the renin-angiotensin sys-
tem has been more and more implicated in the patho-
genesis of clinical hypertensive diseases and has
been considered to play possibly an active role in
normal blood pressure regulation. However, the mea-
surements alone of the different components of this
hormonal system have not sufficed to determine
whether and to what extent the system participates in
blood pressure control [1]. The possibility of specifi-
cally eliminating the action of some of these com-
ponents permitted further exploration of this prob-
lem. One approach to this end was the use of an
angiotensin II analogue, sar'-ala8-angiotensin II (sa-
ralasin), which is a highly specific and effective com-
petitive antagonist of angiotensin II [2]. Such specific
pharmacologic blockade has already been used both
in animals [2—8] and in humans [9—14] to study the
role of angiotensin II and its interaction with the
sodium factor in sustaining renovascular [3—8, 11],
renal [11], malignant [11, 14]', and essential hyperten-
sion [13, 15]. The purpose of the present study was to
investigate the possible role of angiotensin in regu-
lating normal blood pressure. Saralasin was adminis-
tered to normotensive volunteers under conditions of
sodium-depletion and sodium-repletion, and blood
pressure was measured with the subjects in supine as
198 Posternak et a!
well as in standing position. Purposely, the degree of
inflicted sodium-depletion was varied in order to ob-
tain some quantitative evaluation of the sodium bal-
ance critical for blood pressure homeostasis in the
absence of the pressor effect of angiotensin II. We
found that pharmacologic blockade of angiotensin II
induced significant hypotension only when the sub-
jects had lost a considerable amount. of sodium, i.e.,
more than 200 mEq, in most cases, when they were in
addition challenged by upright posture. These results
confirm and expand the findings recently published
by Sancho and coworkers who used an inhibitor of
the converting enzyme in a similar study [16].
Methods
Nine, healthy, male volunteers, 20 to 24 years of
age, were included in the study. All were normoten-
sive (see Table 1). An initial workup, including mea-
surement of plasma and urine electrolytes, blood urea
nitrogen, fasting blood sugar, and creatinine clear-
ance, was done to exclude any latent abnormality.
For each volunteer, the study lasted twelve days.
During the first six days, they were placed on a con-
stant low sodium diet containing 10 mEq of sodium
and 60 mEq of potassium per day. During days 7 to
12, they were switched to a diet with normal sodium
content (100 mEq of sodium and 60 mEq of potas-
sium per day). In order to potentiate sodium-deple-
tion during the first six days, subjects 1, 2,7, 8, and 9
received 100 mg per os of chlorthalidone on day one,
and subjects 1, 2, and 8 another 100 mg on day two.
On days 6 and 12, after stabilization of the blood pres-
sure in the supine position for at least 60 mm, an i.v.
infusion of the angiotensin II inhibitor sar'-ala8-an-
giotensin II (saralasin) was started at the rate of
10 tg/kg of body wt per mm. When steady state
conditions were achieved after 60 to 90 mm, the
subject was asked to assume the erect position for 30
mm. In some instances this could not be accom-
plished because of dizziness and fainting. Blood pres-
sures were monitored at two- to five-minute intervals
using a mercury sphygmomanometer.
Diets were prepared by a research dietician. So-
dium intakes were calculated and then spot-checked
by diet analysis.
Blood samples for the determination of baseline
plasma renin activity were collected on the 5th and
11th day of the study with the volunteers in the
upright position. During the day of the infusion, i.e.,
days 6 and 12, blood samples for the measurement of
plasma renin activity were collected with the subject
in supine position before and 60 to 90 mm after the
saralasin infusion was begun. Finally, a third blood
sample was drawn after the subject had assumed the
erect position for 30 mm, or at the moment of faint-
ing.
Plasma renin activity was determined by radio-
immunoassay, measuring generated angiotensin I af-
ter three hours' incubation, and the results were ex-
pressed as ng/ml/hr [l7}. In our laboratory, the
mean variation of the same sample in 22 consecutive
assays was 3.3% with a range from 0 to 7.3%.
Table 1. Blood pressure response of subjects to i.v. infusion of saralasin.
Day
Chlor-
thai-
Blood pressures, mmHg Cumulative
sodium
balancec
mEq
Day 1 Day 7
Weight change
kg
Day I Day 7
Day 6 Day 12
Control Saralasin Control Saralasin
Subject idoneb to to to to
No. tng Erect Supine Supine Erect Erect Supine Supine Erect Day6 Day 12 Day6 Day 12
Responders
1 200 100/70 100/70 100/60 (75/40) 115/66 110/55 110/60 110/80 —418 +489 —3.8 +3.2
2 200 110/75 120/70 90/60 (50/60) 120/60 100/60 110/70 100/75 —437 +474 —3.9 +2.7
3 0 130/78 135/70 130/78 (70/50) 130/66 132/68 130/68 128/78 —213 +150 —2.1 +0.8
7 100 108/70 100/68 95/62 (30/?) 110/68 105/65 108/72 110/80 —321 +410 —2.7 +1.8
8 200 120/70 120/70 (60/30) — 105/65 108/65 112/66 105/65 —376 +393 —3.3 +2.2
Non-
responders
4 0 120/70 110/58 114/60 120/80 116/68 114/56 114/68 120/80 —98 +185 —2.1 +0.5
5 0 114/74 105/65 102/70 105/74 104/66 95/58 100/60 100/70 —66 +15! —2.1 +0.3
6 0 110/78 130/72 130/75 120/78 128/68 122/70 126/72 110/75 —12 +130 —1.6 +0.7
9 100 130/72 140/80 130/62 115/68 105/65 122/70 125/75 128/78 —152 +256 —0.4 +0.5
Responders and nonresponders: see text for definition. ( ) = Lowest blood pressure measured. Pressure dropped even further but could
not be determined with accuracy because of subject fainting.
b Total dose of chlorthalidone received on days 1 and 2.
Calculated by cumulating over a period of six days. Daily sodium intake minus daily sodium output minus 5 mEq per day ( insensible
losses) during sodium-depletion and minus 10 mEq per day during sodium repletion.
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Twenty-four-hour urine was collected daily through-
out the study for the measurement of sodium, potas-
sium, and creatinine. Urinary electrolytes were mea-
sured by flame photometry. Cumulative sodium
balances were calculated for the periods of sodium-
depletion and sodium-repletion, respectively. This
was done by substracting urinary sodium excretion
from sodium intake and correcting the value for in-
sensible losses (5 mEq/day during sodium-depletion,
and 10 mEq/day during sodium-repletion). Accord-
ing to whether or not diastolic blood pressure fell by
>20 mm Hg during the infusion of saralasin, subjects
were arbitrarily labelled "responders" or "non-
responders."
All volunteers were fully informed of the study
protocol, and they all signed a written consent form.
The protocol was reviewed and approved by the hu-
man experimentation committee of the Department
of Medicine.
Results
Table 1 summarizes some of the characteristics of
the two groups. Mean control upright systolic and
diastolic blood pressures on the sixth and twelfth
days were not significantly different for the two
groups. The responders averaged 113.6 5.2 systolic
and 72.6 1.7 mm Hg dialstolic on the sixth day, and
116 4.3 systolic and 65 1.3 mm Hg diastolic
(mean SEM) on the twelfth day; the nonresponders
exhibited a mean blood pressure of 118.5 4.4 sys-
tolic and 73.5 1.7 mm Hg dialstolic on the sixth
day, and 113.3 5.6 systolic and 66.8 0.8 mm Hg
dialstolic on the twelfth day. These equal blood pres-
sures occurred in the face of markedly different cu-
mulative sodium balances. Thus, responders had lost
significantly more sodium during the first six days
than the nonresponders, i.e., 353 40 mEq as com-
pared to 82 29 mEq for the nonresponders (mean
SEM). This difference was due mainly to a more
extensive use of diuretics on days one and two in the
responder group.
On the sixth day in the sodium-depleted state, five
of the nine volunteers responded to the infusion of
saralasin with a marked fall in blood pressure (Table
1). In all five subjects, the decrease of diastolic blood
pressure exceeded 20 mm Hg, and all developed
symptoms of hypotension, i.e., tachycardia, dizzi-
ness, cold perspiration, and fainting. The drop in
blood pressure occurred in four of the responders
only while standing. The maximal extent of this
blood pressure reduction could not be quantitated
with precision, because all subjects were fainting and
needed to lie down immediately upon measurement
of the blood pressure. The fall occurred in all four
subjects within two to five minutes after assuming the
erect position. One subject, no. 8, was unable to stand
up because of marked blood pressure fall while still
supine. He actually developed a clinical picture of
shock, reversed by rapid infusion o1500 ml of saline.
The other responders also exhibited a slight trend to
lower their blood pressure while still in the supine
position. This trend, however, cannot be considered
physiologically significant, since it may be simply due
to some relaxation of the volunteer following the
start of the infusion.
In contrast, none of the nonreponders experienced
a drop in blood pressure during angiotensin II inhibi-
tion by saralasin either in the supine or in the upright
position. Equally, on the 12th day in the sodium-
replete state, none of the volunteers exhibited a signif-
icant blood pressure drop during the infusion with
saralasin, either in the supine or in the upright posi-
tion (Table 1).
Figure 1 depicts a representative study comparing
blood pressure levels during angiotensin II blockade
on day 6 with those obtained on day 12. Angiotensin
II inhibition did not change blood pressure while the
subject was lying down. However, on day 6, when
sodium-depleted, the volunteer fainted almost imme-
diately after standing up. In contrast, on day 12 when
sodium-repleted, he remained upright during 30 mm
without exhibiting any symptoms or signs of hypo-
tension.
Table 2 and Figure 2 summarize the renin results
on days 5,6, 11, and 12, before and during saralasin
infusion. On day 5, upright plasma renin levels of the
responders reached 41.4 9.4 ng/ml/hr (mean
SEM). In the supine position on the morning of day 6,
plasma renin level was 32.7 7.2 ng/ml/hr. Sub-
sequent angiotensin II blockade by saralasin resulted
in a steep increase of plasma renin level to 133.3
42.9 ng/ml/hr. Upon assuming the erect position, no
further significant change of renin occurred (116.3
50.7 ng/ml/hr). During the same period, the non-
responders showed essentially the same pattern of
response. Thus, the plasma renin level was 14.7 5.1
ng/ml/hr on the 5th day, and 9.3 4.6 ng/ml/hr on
the morning of the 6th day, with subjects in the
supine position. Saralasin infusion stimulated renin
to a plasma level of 26.8 21.1 ng/ml/hr and, with
the subjects assuming the erect position, resulted in a
further increase to 50 21.7 ng/ml/hr. However,
each of these mean renin values of the nonresponders
was clearly lower than the corresponding value of the
responders. Furthermore, the increase in plasma re-
nm level induced by saralasin appears to be less steep
in the nonresponder group than in the responder
group.
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In the sodium-replete state, both groups showed a
similar renin characteristic (Fig. 2, lower panel).
Thus, while the control values of the responder group
on the 11th day were still slightly higher than the
corresponding values of the nonresponders, both
groups exhibited indistinguishable renin levels on the
morning of the 12th day and following 60 to 90 mm
of saralasin infusion while the subjects were supine.
Only on standing up did the responders again in-
crease their plasma renin activity slightly more than
the nonresponders. In contrast to the response ob-
served during sodium-depletion, in the sodium-re-
plete state when renin values were rather low, in-
fusion of saralasin did not seem to have a stimulatory
effect on renin release.
Figure 3 finally depicts the relationship between
control renin values on the fifth day and the cumula-
tive sodium balance on the sixth day. A highly signifi-
cant correlation between these two parameters is ap-
parent (r = 0.86). Notwithstanding, in this limited
number of observations, the responders appear to be
better discriminated from the nonresponders by using
cumulative sodium balance as a criterion rather than
plasma renin levels. Thus, one subject with an already
very high renin value of 30 ng/ml/hr did not respond
to angiotensin II blockade, whereas another subject
with a renin value of only 12 ng/ml/hr did exhibit a
marked blood pressure drop.
Discussion
Time, rn/n
Fig. I. Representative study of angiotensin ii blockade in a normal
volunteer: blood pressure effect depending on sodium balance and
posture. During sodium-depletion, saralasin infusion induces se-
vere orthostatic hypotension. Following sodium-repletion, sarala-
sin has no effect on blood pressure.
Out of nine normal volunteers, only the five who
were more vigorously sodium-depleted exhibited a
significant blood pressure reduction during angioten-
sin II blockade by saralasin. Indeed, blood pressure
reduction could only be induced when the subjects
were markedly sodium-depleted, i.e., if a cumulative
Table 2. Plasma renin levels of subjects before and during saralasin infusion
Plasma renin activity, ng/ml/hr
Day6 Day6 Day 12 Day 12
DayS Day 6 supine upright Day II Day 12 supine upright
Subject no. upright supine +AP upright supine +Al +Ar
Responders
I 67 44 — — 8.7 1.8 0.8 15
2 48 36 217 179 7.3 1.3 0.6 II
3 12 8.6 14 16 3.2 1.8 1.2 2.3
7 30 26 141 154 6.5 1.1 0.7 2.2
8 50 49 l6P' — 8.1 1.3 0.8 4.7
Nonresponders
4 9.5 5.3 5.6 20 2.6 0.9 0.5 4.4
5 9.5 4.6 8.6 39 2.8 2.4 1.3 3.7
6 9.7 4.4 3.1 27 3,0 1.0 0.7 8.9
9 30 23 90 114 7.0 2.0 1.6 4.7
Al angiotensin 11 inhibitor.
Renin drawn while the subject was fainting.
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Sodium-depletion (days 5 and 6)
Upright Supine Supine + Upright +
Angio-inhib. Angio—inhib.
Sodium—repletion (days 11 and 12)
Upright Supine Supine + Upright +
Angio-inhib. Angio—inhib.
Fig. 2. Effect of angiotensin II blockade on plasma renin activity of
normal subjects. Renin responses of responders are represented by
closed circles; () and renin responses of nonresponders are repre-
sented by the open circles (0). If renin levels are high, angiotensin
II blockade induces a further increase (see text).
sodium loss of at least 160 to 200 mEq had been
inflicted. In three of the four subjects who had not
received any diuretics, low sodium diet alone was not
sufficient to achieve this degree of sodium-depletion.
On the other hand, four of the five responders had
taken diuretics to enhance the excretion of sodium.
Even then, in four of the responding volunteers,
blood pressure reduction occurred only when they
assumed the upright position. The four subjects who
received insufficient or no diuretic treatment, and
thus did not achieve a cumulative sodium loss ex-
ceeding 160 mEq, did not exhibit a reduction in blood
pressure when circulating angiotensin II was blocked
by saralasin. Moreover, following sodium-repletion,
none of the volunteers responded to angiotensin II
blockade with a change in blood pressure.
In general, the present observations are in agree-
ment with some earlier findings. Thus, in previous
experimental work in normotensive sodium-depleted
rats [4], we had induced a significant decrease in
blood pressure by blocking angiotensin II. Similarly,
following sodium-repletion, no change in blood pres-
sure was observed during angiotensin II inhibition.
Sancho and coworkers [161 had similar results when
administering an inhibitor of the converting enzyme
to normal volunteers on a tilt table. This compound
blocks the conversion of angiotensin I to the active
pressor hormone angiotensin II. Subjects treated in
that way exhibited a significant blood pressure drop
when sodium-depleted and standing. However, it is
still not clear whether the observed effect can be
attributed solely to the inhibition of angiotensin H,
since inhibition of the converting enzyme also slows
inactivation of bradykinin, which may result in an
accumulation of this vasodilating peptide [18]. Ac-
cordingly, the observed fall in blood pressure might
have been due partly to an accumulation of brady-
kinin and only partly to the reduction in circulating
angiotensin II. The fact that these investigators could
not find an increase in plasma bradykinin levels in the
three subjects in whom these levels were measured
does not exclude this possibility, since bradykinin
may act as a local tissue hormone in the arteriolar
wall rather than in the general circulation.
The present findings together with the previous
observations suggest that angiotensin II plays no role
in the maintenance of normal blood pressure under
conditions of regular sodium intake. Only under con-
ditions of extreme sodium-depletion and associated
hypovolemia does the renin-angiotensin system seem
to play a significant role in maintaining normal blood
pressure levels. It is noteworthy that massive cate-
cholamine secretion as evidenced by clinical signs of
pallor, sweating, tachycardia, etc. was incapable of
sustaining blood pressure under these conditions,
possibly because its vasopressor effect was impaired
in the absence of the permissive action of the sodium
ion [19]. Thus, the renin-angiotensin system appears
to represent an extremely important mechanism
maintaining normal blood pressure under conditions
of severe hypovolemia.
It is possible that some increase in catecholamine
secretion may have occurred during angiotensin II
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Fig. 3. Correlation between plasma renin levels and cumulative so-
dium balance of responders (•) and non-responders (0) to angioten-
sin II blockade. Discrimination between responders and non-
responders appears to depend more strongly on sodium balance
rather than on plasma renin activity.
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blockade even in the sodium-replete state, thus, con-
tributing to peripheral resistance and maintenance of
unchanged blood pressure. Alternatively, cate-
cholamines could have increased cardiac output via
venoconstriction and increased venous return which
would also have resulted in maintenance of a normal
blood pressure. Both of these possible compensatory
mechanisms could have masked an effect of angioten-
sin II blockade in a setup where only blood pressure
is measured and not the associated hemodynamic
parameters, i.e., cardiac output and total peripheral
resistance [20].
When subjects assume the upright posture, con-
striction of the capacitance vessels, i.e., the venous sys-
tem, is necessary to maintain adequate venous return
and thereby cardiac output. Venous tone is probably
catecholamine rather than angiotensin H-dependent,
as angiotensin II has been shown to have very little
effect on the smooth muscles of the veins [21]. In this
context, it may appear surprising that angiotensin II
blockade was most effective with the subj.ects in the
erect position when venous return rather. than pe-
ripheral arterial resistance would seem most critical
to maintain blood pressure. It is conceivable that
during extreme sodium-depletion even maximal cate-
cholamine secretion is hardly sufficient to maintain
adequate venous return and cardiac output. Possibly,
to compensate for some decrease in cardiac output,
renin secretion and generation of angiotensin II is
necessary to increase total peripheral resistance in
order to maintain normotension. Since blockade of
the sympathetic and catecholamine system will
equally lower blood pressure, as is known from phar-
macologic studies using sympatholytic drugs [22],
both of these systems, i.e., the sympathetic as well as
the renin-angiotensin system, must be intact in order
to effectively regulate blood pressure.
The present data confirm once more that angioten-
sin II blockade may stimulate renin secretion. There
appears to exist a relationship between the potency of
the renin stimulating effect of angiotensin II blockade
and the control level of renin. Thus, if the baseline
renin value is high, angiotensin II blockade induces a
further marked increase in renin secretion. If, how-
ever, control renin is rather low, renin may rise little
in response to angiotensin II blockade or, as has been
observed in all our sodium-replete subjects, renin
stimulation may actually be altogether absent despite
equal dose of the angiotensin II inhibitor. These ob-
servations suggest that the negative feedback inhibi-
tion of renin secretion by angiotensin II becomes only
operative when circulating angiotensin II levels are
elevated. However, the present data do not exclude
the possibility that renin is only stimulated when
blood pressure is reduced.
During angiotensin II blockade the response of
renin secretion to a change in posture appears to be
preserved. Thus, in the sodium-deplete as well as in
the sodium-replete state, an increase in plasma renin
levels was observed when the subjects were erect.
Only in the sodium-depleted responders was this ef-
fect not consistently present. Probably, this was
partly due to the subjects' inability to maintain the
upright posture for more than a few minutes because
of fainting and partly because they were already max-
imally stimulated.
Acknowledgment
This work was supported by the Fonds National Suisse de
Ia Recherche Scientifique, grant no. 3.2560.74.
Reprint requests to Dr. Hans R. Brunner, Department of Medicine.
Centre Hospitalier Universitaire, 1011 Lausanne, Switzerland.
References
I. BRUNNER HR, GAVRAS H: Clinical implications ofrenin in the
hypertensive patient. fAin MedAssoc 233:1091, 1975
2. PALS DT, MAsucci FD, Sii'os F, DENNING GS: A specific
competitive antagonist of the vascular action of angiotensin II.
C'irc Res 29:664—672, 1971
3. BRUNNER HR, KIRSHMANN 3D, SEALEY, JE, LARAGH JH: Hy-
pertension of renal origin: Evidence for two different mecha-
nisms. Science 174:1344—1346, 1971
4. GAVRAS H, BRUNNER HR, VAUGHAN ED, LARAGH JH: Angio-
tensin-sodium interaction in blood pressure maintenance of
renal hypertensive and normotensive rats. Science
180:1369—1372, 1973
5. GAVRAS H, BRUNNER HR, THURSTON, H, LARAGH JH: Recip-
rocation of renin-dependency with sodium volume depend-
ency. Science 188: 1316—1317, 1975
6. MILLER, ED, SAMUELS AJ, HABER E, BARGER AC: Inhibition
ofangiotensin conversion in experimental renovascular hyper-
tension. Science 177:1108—1109, 1972
7. KRIEGER EM, SALGADO HC, ASSAN CJ, GREEN LU, FER-
REIRA SH: Potential screening test for detection of overactivity
of renin-angiotensin system. Lancet 1:269—271, 1971
8. BUMPUS FM, SEN S, SMEllY RR, SWEET C, FERRARIO CM,
KHOSLA MC: Use of angiotensin antagonists in experimental
hypertension. Circ Res 32—33 (suppl. 1): 150—158, 1973
9. BRUNNER 1-IR,GAVRAS H, LARAGH ill, KEENAN R: Angioten-
sin 11 blockade in man by sar1-ala8-angiotensin II for under-
standing and treatment of high blood pressure. Lancet
2:1045—1048, 1973
10. BRUNNER HR, GAVRAS H, LARAGH JH, KEENAN R: Hyperten-
sion in man. Exposure of the renin and sodium components
using angiotensin II blockade. Circ Res 34—35 (suppl. 1):
35—46, 1974
II. BRUNNER FIR, GAVRAS H: The role of renin and sodium in
high blood pressure regulation, in Pat hophrsiologi and Man-
agcnlent of Arterial Hypertension, edited by BERGLUND G,
HANSSON L, WERKO L, Mdlndal, Hassle AB, 1975. pp.
32—42
12. GAVRAS H, BRUNNER HR, LARAGH JH, SEALEY JE, GAVRAS I,
VUKOVICH RA: An angiotensin converting enzyme inhibitor
to identify and treat vasoconstrictor and volume factors in
hypertensive patients. N Engi J Med 291:817—821, 1974
13. STREETEN DHP, ANDERSON GH, FREJBERG JM, DALAKOS
A ngiolensin II and maintenance of blood pressure 203
TG: Use of an angiotensin antagonist (saralasin) in the recog-
nition of "angiotensinogenic" hypertension. N Engi J Med
296:657—662, 1975
14. JOHNSON JG, BLACK WD, VUKOVICH RA, HATCH FE JR,
FRIEDMAN B!, BLACKWELL CF, SHENOUDA AN, SHARE L,
SHADE RE, ACCHIARDO SR, MUIRHEAD EE: Treatment of
patients with severe hypertnsion by inhibition of angiotensin-
converting enzyme. Clin Sci Mo! Med 48(suppl. 2):53s—56s,
1975
15. GAVRAS H, RIBEIRO AB, GAVRAS 1, BRUNNER HR: Reciprocal
relationship between renin dependency and sodium depend-
ency in essential hypertension. N Engi J Med 295:1278—1283,
1976
16. SANCHO J, RE R, BURTON J, BARGER AC, HABER E: The role
of the renin-angiotensin-aldosterone system in cardiovascular
homeostasis in normal human subjects. Circulation
53:400—405, 1976
17. SEALEY JE, GERTEN—BANES J, LARAGH JH: The renin system
variation in man measured by radioimmunoassay or bioassay.
Kidney In! 1:240—253, 1972
18. COLLIER JG, RoBINsoN BF, VANE JR: Reduction of pressor
effects of angiotensin I in man by synthetic nonapeptide
(B.P.P. or SQ 20881) which inhibits converting enzyme. Lan-
ce! 1:72—74, 1973
19. RAAB W, HUMPHREYS Ri, MAKOUS N, DEGRANDPRE R,
GIGEE W: Pressor effects of epinephrine, norepinephrine and
desoxycorticosterone acetate (DCA) weakened by sodium
withdrawal. Circulation 6:373—377, 1952
20. ISHIKAWA I, HOLLENBERG NK: Blockade of the systemic and
renal vascular actions of angiotensin II with the 1-sar, 8-ala
analogue in the rat. Life Set 17:121—130, 1975
21. FOLKOw B, JOHANSON B, MELANDER 5: The comparative
effects of angiotensin and noradrenalin on consecutive vascu-
lar sections. Acta Physiol Scand 53:99, 1961
22. GOODMAN LS, GILMAN A: The Pharmacological Basis of Ther-
apeutics. London, Toronto, The Macmillan Company, 1971
